FI63757C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat Download PDFInfo
- Publication number
- FI63757C FI63757C FI436/73A FI43673A FI63757C FI 63757 C FI63757 C FI 63757C FI 436/73 A FI436/73 A FI 436/73A FI 43673 A FI43673 A FI 43673A FI 63757 C FI63757 C FI 63757C
- Authority
- FI
- Finland
- Prior art keywords
- quinoxaline
- formula
- compound
- quinazoline
- och
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919672A GB1381979A (en) | 1972-02-29 | 1972-02-29 | Amino derivatives of quinoline quinoxaline and quinazoline |
| GB919672 | 1972-02-29 | ||
| GB5162972 | 1972-11-08 | ||
| GB5162972 | 1972-11-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI63757B FI63757B (fi) | 1983-04-29 |
| FI63757C true FI63757C (fi) | 1983-08-10 |
Family
ID=26242776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI436/73A FI63757C (fi) | 1972-02-29 | 1973-02-14 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3890319A (hu) |
| JP (2) | JPS5754516B2 (hu) |
| AR (1) | AR213705A1 (hu) |
| AU (1) | AU471598B2 (hu) |
| BE (1) | BE795970A (hu) |
| CA (1) | CA981678A (hu) |
| CH (2) | CH577500A5 (hu) |
| DE (1) | DE2309160A1 (hu) |
| ES (2) | ES411804A1 (hu) |
| FI (1) | FI63757C (hu) |
| FR (1) | FR2181776B1 (hu) |
| GB (1) | GB1381979A (hu) |
| IE (1) | IE37519B1 (hu) |
| MX (1) | MX3042E (hu) |
| NL (1) | NL159102B (hu) |
| SE (1) | SE417204B (hu) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
| JPS5373571A (en) * | 1976-12-10 | 1978-06-30 | Otsuka Pharmaceut Co Ltd | Carbostyril derivatives |
| JPS542338A (en) | 1977-04-22 | 1979-01-09 | Sandoz Ag | Pharmaceutical composition |
| US4188393A (en) | 1977-04-22 | 1980-02-12 | Sandoz Ltd. | Treating spastic conditions or relaxing muscles |
| FR2449087A2 (fr) * | 1979-02-16 | 1980-09-12 | Rhone Poulenc Ind | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4486432A (en) * | 1982-09-30 | 1984-12-04 | Eli Lilly And Company | Quinoxalinedione leukotriene release inhibitors |
| FR2541680B1 (fr) * | 1983-02-24 | 1985-06-14 | Rhone Poulenc Sante | Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent |
| JPS6118950U (ja) * | 1984-07-10 | 1986-02-03 | 財団法人鉄道総合技術研究所 | トロリ線の給油装置 |
| JPS63296814A (ja) * | 1987-05-29 | 1988-12-02 | Ishigaki Kiko Kk | 集塵装置における濾材の目詰り除去装置 |
| GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5180721A (en) * | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5281591A (en) * | 1989-05-22 | 1994-01-25 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5204347A (en) * | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
| US5326763A (en) * | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5198442A (en) * | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5215991A (en) * | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
| US5237072A (en) * | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5130441A (en) * | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5252595A (en) * | 1990-02-28 | 1993-10-12 | Allergan, Inc. | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines |
| US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| JP3683908B2 (ja) * | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法 |
| US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5580892A (en) * | 1993-10-22 | 1996-12-03 | Allergan | Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents |
| US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| PL180392B1 (pl) * | 1993-12-17 | 2001-01-31 | Procter & Gamble | Zwiazki 6-(2-imidazolinyloamino)chinolinoweprzydatne jako agonisci a-2-adrenoceptorów i kompozycje farmaceutyczne je zawierajace PL PL PL PL PL PL PL PL |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| DE69425334T2 (de) * | 1993-12-17 | 2001-02-08 | Procter & Gamble | 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten |
| AU677513B2 (en) * | 1994-02-08 | 1997-04-24 | Alcon Laboratories, Inc. | Novel process for preparation of clonidine derivatives |
| WO1996004270A1 (en) | 1994-08-04 | 1996-02-15 | Synaptic Pharmaceutical Corporation | Novel benzimidazole derivatives |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5916900A (en) * | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| ES2236833T3 (es) | 1996-11-25 | 2005-07-16 | THE PROCTER & GAMBLE COMPANY | Compuestos heterociclicos de guanidinilo utiles como agonistas de receptores adrenergicos alfa 2. |
| KR20000069128A (ko) * | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물 |
| HUP9904215A3 (en) * | 1996-11-25 | 2002-01-28 | Procter & Gamble | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
| WO1998023612A1 (en) * | 1996-11-25 | 1998-06-04 | The Procter & Gamble Company | 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists |
| US6172095B1 (en) | 1996-11-25 | 2001-01-09 | The Procter & Gamble Company | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6306877B1 (en) | 1999-08-09 | 2001-10-23 | The Procter & Gamble Co. | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| EP1037887B1 (en) | 1997-11-24 | 2004-07-14 | The Procter & Gamble Company | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| US6242442B1 (en) | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
| US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| RU2311928C2 (ru) | 2000-07-14 | 2007-12-10 | Аллерган Инк. | Композиции, содержащие альфа-2-адренергические агонисты |
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| BR0112461A (pt) | 2000-07-14 | 2003-07-22 | Allergan Inc | Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada |
| DE10161767A1 (de) * | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
| ATE429216T1 (de) * | 2002-10-08 | 2009-05-15 | Allergan Inc | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson |
| US20040116436A1 (en) * | 2002-10-08 | 2004-06-17 | Tatton William G. | Treatment of dementia and parkinson's disease |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| AU2004263149B2 (en) | 2003-08-07 | 2010-08-19 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| NZ545459A (en) * | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| WO2005039567A1 (en) * | 2003-10-08 | 2005-05-06 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| MXPA06013649A (es) | 2004-05-25 | 2007-07-09 | Sansrosa Pharmaceutical Dev In | Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel. |
| US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
| NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
| US8648087B2 (en) | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
| US7842714B2 (en) | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| ES2756499T3 (es) | 2009-10-06 | 2020-04-27 | Allergan Inc | Derivados de 2H-pirrol-5-amina como moduladores de receptor alfa adrenérgico |
| EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
| WO2011117378A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| WO2011117377A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
| AU2011237677A1 (en) | 2010-04-07 | 2012-11-08 | Allergan, Inc. | Combinations of preservative compositions for ophthalmic formulations |
| WO2011127151A2 (en) | 2010-04-07 | 2011-10-13 | Allergan, Inc. | Combinations of preservatives for ophthalmic compositions |
| EP3434257A1 (en) | 2010-07-29 | 2019-01-30 | Allergan, Inc. | Preservative free brimonidine and timolol solutions |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| JP2013540143A (ja) | 2010-10-21 | 2013-10-31 | ガルデルマ・ソシエテ・アノニム | ブリモニジンゲル組成物及び使用方法 |
| KR20140062471A (ko) | 2011-07-25 | 2014-05-23 | 알러간, 인코포레이티드 | 알파 2 아드레날린 수용체의 조절물질로서의 n-(이미다졸리딘-2-일리덴)퀴놀린 유도체 |
| GR1009419B (el) | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560501A (en) * | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| BE766039A (fr) * | 1971-04-21 | 1971-09-16 | Labofina Sa | Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres. |
-
0
- BE BE795970D patent/BE795970A/xx not_active IP Right Cessation
-
1972
- 1972-02-29 GB GB919672A patent/GB1381979A/en not_active Expired
-
1973
- 1973-02-08 AU AU51985/73A patent/AU471598B2/en not_active Expired
- 1973-02-13 SE SE7302024A patent/SE417204B/xx unknown
- 1973-02-14 US US332485A patent/US3890319A/en not_active Expired - Lifetime
- 1973-02-14 IE IE236/73A patent/IE37519B1/xx unknown
- 1973-02-14 FI FI436/73A patent/FI63757C/fi active
- 1973-02-15 MX MX129473U patent/MX3042E/es unknown
- 1973-02-20 ES ES411804A patent/ES411804A1/es not_active Expired
- 1973-02-21 JP JP48020280A patent/JPS5754516B2/ja not_active Expired
- 1973-02-22 CA CA164,361A patent/CA981678A/en not_active Expired
- 1973-02-23 DE DE19732309160 patent/DE2309160A1/de active Pending
- 1973-02-23 AR AR246774A patent/AR213705A1/es active
- 1973-02-27 ES ES412102A patent/ES412102A1/es not_active Expired
- 1973-02-28 FR FR7307157A patent/FR2181776B1/fr not_active Expired
- 1973-02-28 CH CH149075A patent/CH577500A5/xx not_active IP Right Cessation
- 1973-02-28 NL NL7302799.A patent/NL159102B/xx not_active IP Right Cessation
- 1973-02-28 CH CH293873A patent/CH576975A5/xx not_active IP Right Cessation
-
1980
- 1980-07-11 JP JP9493480A patent/JPS5625176A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB1381979A (en) | 1975-01-29 |
| DE2309160A1 (de) | 1973-09-27 |
| CA981678A (en) | 1976-01-13 |
| JPS4897878A (hu) | 1973-12-13 |
| NL159102B (nl) | 1979-01-15 |
| JPS5625176A (en) | 1981-03-10 |
| AU471598B2 (en) | 1976-04-29 |
| AU5198573A (en) | 1974-08-08 |
| FI63757B (fi) | 1983-04-29 |
| CH576975A5 (hu) | 1976-06-30 |
| BE795970A (fr) | 1973-08-27 |
| AR213705A1 (es) | 1979-03-15 |
| MX3042E (es) | 1980-03-04 |
| NL7302799A (hu) | 1973-08-31 |
| IE37519L (en) | 1973-08-29 |
| IE37519B1 (en) | 1977-08-17 |
| JPS5754516B2 (hu) | 1982-11-18 |
| US3890319A (en) | 1975-06-17 |
| ES412102A1 (es) | 1976-05-16 |
| FR2181776A1 (hu) | 1973-12-07 |
| CH577500A5 (hu) | 1976-07-15 |
| JPS5745439B2 (hu) | 1982-09-28 |
| FR2181776B1 (hu) | 1976-08-13 |
| SE417204B (sv) | 1981-03-02 |
| ES411804A1 (es) | 1976-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI63757C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat | |
| US4029792A (en) | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents | |
| AU679049B2 (en) | Antipsychotic benzimidazole derivatives | |
| HU211256A9 (en) | New benzimidazolone derivatives | |
| AU757290B2 (en) | Imidazolone anorectic agents: II. phenyl derivatives | |
| DK158838B (da) | Quinazolinderivater, en fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende derivater samt anvendelse af derivaterne til fremstilling af medikamenter | |
| JPH0219112B2 (hu) | ||
| JPH054983A (ja) | イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤 | |
| JPH03133964A (ja) | ピリミジン誘導体 | |
| IE66111B1 (en) | Hydrazone derivatives their preparation and use | |
| US3466274A (en) | Fluoreno-(1,9-ef)-1,4-diazepine-1-oxides and 1,3-diazafluoranthene-1-oxides | |
| US3300494A (en) | Pyrazinamidoguanidine products | |
| JP2008516975A (ja) | 化合物 | |
| CZ280018B6 (cs) | 4-alkylimidazolové deriváty | |
| JPH04139173A (ja) | ２−アミノピリミジン−４−カルボキサミド誘導体、その製造法およびそれを含有する医薬 | |
| JPH02138266A (ja) | ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体 | |
| US3314963A (en) | Azabenzocycloalkane-n-carboxamidines | |
| AU2009292437A1 (en) | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent | |
| JP2006516565A (ja) | 治療薬を製造するための２−アミノ−２ｈ−キナゾリン誘導体の使用 | |
| WO1997005129A1 (fr) | (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, son procede d'obtention et medicament le contenant | |
| SU927111A3 (ru) | Способ получени оксимэфиров или их солей | |
| HU196408B (en) | Process for producing tetrahydro-imidazo-quinazolines and stimulators of cardiac action containing them | |
| NO126799B (hu) | ||
| JP5006505B2 (ja) | 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体 | |
| JPH01319487A (ja) | イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 |